Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H8 Trial in Stage I-II Hodgkin's Lymphoma
NCT00379041Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 1993
- Primary completion
- Oct 1998
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
01
Overview
Phase 3, randomised, open-label trial of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin and 2 more in Hodgkin lymphoma (HL) (6 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Overall Survival up to 10 years, Reduction of late treatment-related toxicity up to 10 years and 1 more. Started Sep 1993; status: active, not recruiting.
02
Drugs
mechlorethaminevincristineprocarbazineprednisonedoxorubicin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00379041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379041.